RT Journal Article
T1 Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain.
A1 Deza, Gustavo
A1 Notario, Jaime
A1 Ferran, Marta
A1 Beltrán, Emma
A1 Almirall, Miriam
A1 Alcalá, Rebeca
A1 Ruiz-Carrascosa, José Carlos
A1 Sánchez, Ricardo
A1 Pérez, Silvia
A1 García-Vivar, María Luz
A1 Galíndez, Eva
A1 Mora, Maribel
A1 Rodríguez, Jesús
A1 Gallardo, Fernando
K1 Arthritis
K1 Etanercept
K1 Psoriasis
K1 Psoriatic
K1 Survival
K1 TNF-α blockers
AB Although several randomized clinical trials and observational studies have evaluated the effectiveness, safety and drug survival of etanercept (ETN) in the treatment of psoriatic arthritis (PsA), long-term data regarding these aspects are currently scarce. For this reason, we sought to investigate the long-term survival and safety of ETN in PsA patients in 4 tertiary care Spanish hospitals over a 13-year observation period (from 2004 to 2017). The records of 85 PsA patients were reviewed. ETN showed an excellent survival profile, with rates of treatment discontinuation at 1, 3, 5 and 10 years of 15, 37, 46 and 59%, respectively. In our cohort, a trend toward longer drug survival in patients with shorter disease duration and those who were treated with ETN as their first biologic agent was observed. On the other hand, combination therapy with conventional disease-modifying antirheumatic drugs did not provide greater improvement on the long-term drug survival. Only 12% of the patients reported adverse events (AEs) during therapy, being most of them of mild to moderate intensity, and in only 7% AEs led to drug discontinuation. To the best of our knowledge, the present study shows the largest follow-up period of ETN-treated population analyzed in a real-life setting, and these results demonstrate the positive safety profile and long-term effectiveness of this biologic agent in the management of PsA patients.
YR 2018
FD 2018-08-24
LK http://hdl.handle.net/10668/12870
UL http://hdl.handle.net/10668/12870
LA en
DS RISalud
RD Apr 19, 2025